Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease
04. April 2022 06:30 ET
|
Verve Therapeutics
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st...
Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
24. März 2022 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
14. März 2022 06:30 ET
|
Verve Therapeutics
Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight...
Verve Therapeutics to Present at the Cowen 42nd Annual Healthcare Conference
23. Februar 2022 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing...
Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs
10. Januar 2022 06:30 ET
|
Verve Therapeutics
VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data...
Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
03. Januar 2022 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...
Verve Therapeutics Appoints Allison Dorval, Experienced Financial Executive, as Chief Financial Officer
29. November 2021 08:00 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course...
Verve Therapeutics Announces Pipeline Progress and Reports Third Quarter 2021 Financial Results
10. November 2021 06:30 ET
|
Verve Therapeutics
VERVE-101 Preclinical Data Announced at TIDES 2021 Demonstrated Potent, Durable PCSK9 Protein and LDL-C Reductions, Supporting Planned Clinical Initiation in 2022 New Preclinical Data from ANGPTL3...
Verve Therapeutics Reports Preclinical Data Demonstrating Potent Editing of ANGPTL3 Gene Using Proprietary GalNAc-LNP Delivery Technology in Non-Human Primates
09. November 2021 06:30 ET
|
Verve Therapeutics
ANGPTL3 Base Editor Delivered via Internally Developed GalNAc-LNPs Potently Reduced Blood ANGPTL3 Protein by 94-97% in a Novel NHP Model of Homozygous Familial Hypercholesterolemia GalNAc-LNP...
Verve Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit
21. Oktober 2021 06:30 ET
|
Verve Therapeutics
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines,...